Analysts rating. Read wallstcheatsheet. 9 dollar target!
"According to Roth capital, recent weakness in Curis was due to statements made by a physician who innacurately described the resistance rates of Curis Erivedge. The firm keeps its buy rating and a $9 price target on the stock."
That is nice to hear, but highly doubtful that this Roth Capital opinion would triple the volume and make the stock jump like it did today.
Hoping for real news next week!
I sincerely doubt if something on wallstcheatsheet would drive this....